These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20012916)

  • 21. Estimation of liver function using T2* mapping on gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid enhanced magnetic resonance imaging.
    Katsube T; Okada M; Kumano S; Imaoka I; Kagawa Y; Hori M; Ishii K; Tanigawa N; Imai Y; Kudo M; Murakami T
    Eur J Radiol; 2012 Jul; 81(7):1460-4. PubMed ID: 21514080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gd-DTPA-DeA: a novel, liver-specific MRI contrast agent.
    Kawamura Y
    Acad Radiol; 2002 May; 9 Suppl 1():S102-3. PubMed ID: 12019839
    [No Abstract]   [Full Text] [Related]  

  • 23. Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8.
    Yoneda N; Matsui O; Kitao A; Kozaka K; Gabata T; Sasaki M; Nakanuma Y; Murata K; Tani T
    Jpn J Radiol; 2012 Nov; 30(9):777-82. PubMed ID: 22911100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Receiver operating characteristic curve analysis, sensitivity comparison and individual difference.
    Kawada T
    Clin Radiol; 2012 Sep; 67(9):940. PubMed ID: 22608247
    [No Abstract]   [Full Text] [Related]  

  • 25. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA.
    Jung G; Breuer J; Poll LW; Koch JA; Balzer T; Chang S; Mödder U
    Acta Radiol; 2006 Feb; 47(1):15-23. PubMed ID: 16498928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contrast-enhanced MRI of focal liver tumors using a hepatobiliary MR contrast agent: detection and differential diagnosis using Gd-EOB-DTPA-enhanced versus Gd-DTPA-enhanced MRI in the same patient.
    Hammerstingl R; Zangos S; Schwarz W; Rosen T; Bechstein WO; Balzer T; Vogl TJ
    Acad Radiol; 2002 May; 9 Suppl 1():S119-20. PubMed ID: 12019845
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats.
    Tsuda N; Harada K; Matsui O
    J Gastroenterol Hepatol; 2011 Mar; 26(3):568-76. PubMed ID: 21332553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correction to The Dixon technique and the frequency-selective fat suppression technique in three-dimensional T1 weighted MRI of the liver: a comparison of contrast-to-noise ratios of hepatocellular carcinomas-to-liver.
    Br J Radiol; 2016 Oct; 89(1066):20150117e. PubMed ID: 27572243
    [No Abstract]   [Full Text] [Related]  

  • 29. [Evaluation of breath-hold multislice dynamic MRI of hepatocellular carcinomas].
    Itoh K; Honjo K; Honma Y; Hatanaka M; Choji T; Uchisako H; Kuramitsu T; Tanaka N; Nakaki H; Matsumoto T
    Nihon Igaku Hoshasen Gakkai Zasshi; 1992 Mar; 52(3):399-401. PubMed ID: 1315953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric mouse model for MRI contrast agent evaluation.
    Mir FF; Tomaszewski RP; Shuboni-Mulligan DD; Mallett CL; Hix JML; Ether ND; Shapiro EM
    Magn Reson Med; 2019 Jul; 82(1):387-394. PubMed ID: 30874333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging.
    Watcharin W; Schmithals C; Pleli T; Köberle V; Korkusuz H; Hübner F; Waidmann O; Zeuzem S; Korf HW; Terfort A; Gelperina S; Vogl TJ; Kreuter J; Piiper A
    J Control Release; 2015 Feb; 199():63-71. PubMed ID: 25499552
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential diagnosis of hepatic tumors with delayed enhancement at gadolinium-enhanced MRI: a pictorial essay.
    Awaya H; Ito K; Honjo K; Fujita T; Matsumoto T; Matsunaga N
    Clin Imaging; 1998; 22(3):180-7. PubMed ID: 9559229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging.
    Watcharin W; Schmithals C; Pleli T; Köberle V; Korkusuz H; Huebner F; Zeuzem S; Korf HW; Vogl TJ; Rittmeyer C; Terfort A; Piiper A; Gelperina S; Kreuter J
    Eur J Pharm Biopharm; 2014 May; 87(1):132-41. PubMed ID: 24365328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Focal liver lesion detection and characterization with GD-EOB-DTPA.
    Purysko AS; Remer EM; Veniero JC
    Clin Radiol; 2011 Jul; 66(7):673-84. PubMed ID: 21524416
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing antiangiogenic therapy response by DCE-MRI: development of a physiology driven multi-compartment model using population pharmacometrics.
    Steingoetter A; Menne D; Braren RF
    PLoS One; 2011; 6(10):e26366. PubMed ID: 22028864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breath-hold spin-echo MR imaging for evaluation of dynamic enhancement of native and treated hepatocellular carcinoma after intravenous Gd-DTPA administration.
    Lencioni R; Mascalchi M; Paolicchi A; Zampa V
    MAGMA; 1995; 3(3-4):151-6. PubMed ID: 8749733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?
    Kudo M
    Oncology; 2010 Jul; 78 Suppl 1():87-93. PubMed ID: 20616589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the intestinal and hepatic uptake/efflux transport of the magnetic resonance imaging contrast agent gadolinium-ethoxylbenzyl-diethylenetriamine-pentaacetic acid.
    Jia J; Puls D; Oswald S; Jedlitschky G; Kühn JP; Weitschies W; Hosten N; Siegmund W; Keiser M
    Invest Radiol; 2014 Feb; 49(2):78-86. PubMed ID: 24056116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Double contrast MR imaging of hepatocellular carcinoma evaluating lesion detection and conspicuity.
    Akinci D; Oto A; Besim A; Akhan O; Abbasoglu O; Batman F; Eryilmaz M
    Acad Radiol; 2002 Aug; 9 Suppl 2():S466-7. PubMed ID: 12188310
    [No Abstract]   [Full Text] [Related]  

  • 40. Will CT take second billing to MR imaging for the diagnosis of hypervascular hepatocellular carcinomas hereafter?
    Kanematsu M
    Radiology; 2011 Aug; 260(2):607; author reply 607-8. PubMed ID: 21778455
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.